Indaptus Therapeutics, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023; filed August 14, 2023. Indaptus is a clinical-stage biotechnology company developing Decoy20, an investigational immunotherapy. It has no approved products and has generated no product-sales revenue.
Financial performance and position
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $1.48 million | $1.51 million | $3.36 million | $2.80 million |
| General and administrative | $2.01 million | $2.36 million | $4.59 million | $4.47 million |
| Total operating expenses | $3.50 million | $3.87 million | $7.95 million | $7.27 million |
| Other income, net | $250,197 | $33,758 | $452,125 | $70,677 |
| Net loss | $3.25 million | $3.84 million | $7.50 million | $7.20 million |
| Net loss per share, basic and diluted | $0.39 | $0.46 | $0.89 | $0.87 |
| Operating cash used | Not presented quarterly | Not presented quarterly | $7.07 million | $6.27 million |
Margins are not meaningful because the company reported no product revenue. Higher interest income contributed to the lower Q2 net loss year over year, while the six-month net loss increased.
| Balance-sheet metric | June 30, 2023 | December 31, 2022 |
|---|---|---|
| Cash and cash equivalents | $12.70 million | $9.63 million |
| Marketable securities | $6.99 million | $16.81 million |
| Cash, cash equivalents and marketable securities | $19.69 million | $26.43 million |
| Total current assets | $19.87 million | $27.24 million |
| Total liabilities | $2.22 million | $3.43 million |
| Accumulated deficit | $37.49 million | $29.99 million |
Six-month investing cash inflow was $10.14 million, chiefly reflecting $17.0 million of marketable-security maturities offset by $6.86 million of purchases. Cash increased by $3.07 million over the six months. No financing cash flows were reported. The company reported no debt; operating lease liabilities totaled $216,591, including $100,421 current. Total future lease payments were approximately $238,000.
Changes versus comparable periods
- Q2 operating expenses declined 10% year over year; R&D was nearly flat and G&A fell 15%, primarily from lower stock-based compensation and directors’ and officers’ insurance costs.
- For the first six months, operating expenses rose 9%. R&D increased 20%, attributed mainly to Phase 1 trial costs and payroll; G&A increased 3%.
- Six-month operating cash use increased by about $0.8 million year over year, which management attributed to higher trial-related R&D and G&A spending.
- Cash and marketable securities combined declined approximately $6.7 million from year-end, although cash and cash equivalents alone increased as securities matured.
Outlook, risks and unusual items
- Going concern: Management said the $19.7 million of cash, cash equivalents and marketable securities was expected to fund operations into Q2 2024 under its current plan. The filing states there is substantial doubt about the company’s ability to continue as a going concern within one year after filing. Additional funding is expected to be needed; availability and acceptable terms are not assured. Failure to obtain funding could force program delays, reductions, elimination or cessation of operations.
- Development: The FDA-cleared Phase 1 Decoy20 trial began in December 2022. The company reported that, in August 2023, four patients completed the first single-dose cohort, with short-lived symptoms or adverse events described as consistent with Decoy20’s mechanism. The Safety Review Committee authorized enrollment in the second cohort. Dose-finding data are intended to inform a recommended Phase 2 dose; multi-dose and combination studies were planned for 2024. These are early, limited clinical observations, not evidence of efficacy.
- Spending outlook: Management expected R&D and G&A expenses to increase as the trial progresses and operations expand. No revenue or profitability guidance was provided.
- Funding avenues: The company cited potential collaborations, strategic alliances, licensing, and debt or equity financing. It reported no sales to date under its up-to-$6.3 million ATM agreement or its up-to-$20 million Lincoln Park purchase agreement. Additional equity financing could dilute shareholders; other funding arrangements could restrict operations or require relinquishing rights.
- Other matters: The LTS arbitration dispute was settled in February 2023 for €800,000; the company said the settlement was below the amount accrued. No material legal proceedings were pending at the filing date. The San Diego office lease was extended through October 2025.
- Principal risks: Clinical and regulatory uncertainty, potential adverse effects, patient enrollment and trial execution, reliance on third-party manufacturers and CROs, intellectual-property protection, competition, and macroeconomic conditions that could limit access to capital. Management reported disclosure controls were effective at the reasonable-assurance level and no material internal-control changes during the quarter.
Most important facts for investors to verify
- Whether financing or partnership arrangements were secured, and whether they materially change the stated cash runway or going-concern risk.
- Enrollment, safety findings and dose-escalation progress in the Decoy20 Phase 1 trial; distinguish preliminary safety observations from efficacy evidence.
- Actual cash burn and R&D spending relative to management’s runway assumptions and planned 2024 studies.
- Potential dilution and terms of any future use of the ATM or Lincoln Park facility, or other equity-linked financing.
- Any updates to clinical timelines, manufacturing capacity, regulatory requirements or material contingencies since the filing.